154 related articles for article (PubMed ID: 21762647)
1. Urinary interleukin-6 (IL-6) and transforming growth factor (TGF-β) levels in corticosteroidtreated patients with IgA nephropathy.
Kalliakmani P; Nakopoulou L; Tsakas S; Gerolymos M; Papasotiriou M; Goumenos DS
Clin Nephrol; 2011 Aug; 76(2):144-50. PubMed ID: 21762647
[TBL] [Abstract][Full Text] [Related]
2. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
3. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy.
Haramaki R; Tamaki K; Fujisawa M; Ikedo H; Haramaki N; Okuda S
Am J Kidney Dis; 2001 Dec; 38(6):1191-8. PubMed ID: 11728950
[TBL] [Abstract][Full Text] [Related]
4. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Park HC; Xu ZG; Choi S; Goo YS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
Nephrol Dial Transplant; 2003 Jun; 18(6):1115-21. PubMed ID: 12748343
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria.
Goumenos DS; Tsakas S; El Nahas AM; Alexandri S; Oldroyd S; Kalliakmani P; Vlachojannis JG
Nephrol Dial Transplant; 2002 Dec; 17(12):2145-52. PubMed ID: 12454225
[TBL] [Abstract][Full Text] [Related]
6. Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type1 and transforming growth factor β1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy.
Segarra-Medrano A; Carnicer-Caceres C; Valtierra-Carmeno N; Agraz-Pamplona I; Ramos-Terrades N; Jatem Escalante E; Ostos-Roldan E
Nefrologia; 2017; 37(5):531-538. PubMed ID: 28946966
[TBL] [Abstract][Full Text] [Related]
7. T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome?
Kalavrizioti D; Gerolymos M; Rodi M; Kalliakmani P; Provatopoulou S; Eleftheriadis T; Mouzaki A; Goumenos DS
Cytokine; 2015 Dec; 76(2):260-269. PubMed ID: 26307557
[TBL] [Abstract][Full Text] [Related]
8. Increased excretion of urinary transforming growth factor beta in patients with focal glomerular sclerosis.
Kanai H; Mitsuhashi H; Ono K; Yano S; Naruse T
Nephron; 1994; 66(4):391-5. PubMed ID: 8015640
[TBL] [Abstract][Full Text] [Related]
9. Changes in urinary angiotensinogen posttreatment in pediatric IgA nephropathy patients.
Urushihara M; Nagai T; Kinoshita Y; Nishiyama S; Suga K; Ozaki N; Jamba A; Kondo S; Kobori H; Kagami S
Pediatr Nephrol; 2015 Jun; 30(6):975-82. PubMed ID: 25523477
[TBL] [Abstract][Full Text] [Related]
10. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria.
Uzu T; Harada T; Ko M; Yamato M; Takahara K; Yamauchi A
Clin Exp Nephrol; 2003 Sep; 7(3):210-4. PubMed ID: 14586717
[TBL] [Abstract][Full Text] [Related]
11. Urinary transforming growth factor-beta in patients with glomerular diseases.
Murakami K; Takemura T; Hino S; Yoshioka K
Pediatr Nephrol; 1997 Jun; 11(3):334-6. PubMed ID: 9203185
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
Tang Y; He H; Sun W; Hu P; Chen X; Xu X
Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive Urinary Monitoring of Progression in IgA Nephropathy.
Yang JYC; Sarwal RD; Fervenza FC; Sarwal MM; Lafayette RA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510053
[TBL] [Abstract][Full Text] [Related]
14. alpha-Tocopherol reduces proteinuria, oxidative stress, and expression of transforming growth factor beta 1 in IgA nephropathy in the rat.
Chan W; Krieg RJ; Norkus EP; Chan JC
Mol Genet Metab; 1998 Mar; 63(3):224-9. PubMed ID: 9608545
[TBL] [Abstract][Full Text] [Related]
15. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis.
Honkanen E; Teppo AM; Törnroth T; Groop PH; Grönhagen-Riska C
Nephrol Dial Transplant; 1997 Dec; 12(12):2562-8. PubMed ID: 9430852
[TBL] [Abstract][Full Text] [Related]
16. Increased excretion of tumor necrosis factor alpha and interleukin 1 beta in urine from patients with IgA nephropathy and Schönlein-Henoch purpura.
Wu TH; Wu SC; Huang TP; Yu CL; Tsai CY
Nephron; 1996; 74(1):79-88. PubMed ID: 8883024
[TBL] [Abstract][Full Text] [Related]
17. Urinary levels of interleukin-6 and disease activity in patients with IgA nephropathy.
Tomino Y; Funabiki K; Ohmuro H; Shimizu M; Yokoyama K; Shirato I; Shirai T; Takahashi M; Koide H
Am J Nephrol; 1991; 11(6):459-64. PubMed ID: 1819212
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic values of serum concentration and urinary excretion of interleukin-1 receptor antagonist and tumor necrosis factor receptors type I and II in patients with IGA nephropathy].
Zwiech R; Kacprzyk F; Szuflet A; Nowicki M
Pol Arch Med Wewn; 2005 Apr; 113(4):326-33. PubMed ID: 16209246
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic findings relevant to disappearance or relapse of proteinuria following corticosteroid treatment in IgA nephropathy patients with proteinuria of 0.5 to 2.0 g/day.
Suzuki T; Yamamoto T; Ohura M; Fujigaki Y; Yonemura K; Kimura M; Hishida A
Clin Exp Nephrol; 2004 Sep; 8(3):243-9. PubMed ID: 15480902
[TBL] [Abstract][Full Text] [Related]
20. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Min L; Wang Q; Cao L; Zhou W; Yuan J; Zhang M; Che X; Mou S; Fang W; Gu L; Zhu M; Wang L; Yu Z; Qian J; Ni Z
Oncotarget; 2017 Jul; 8(29):48375-48384. PubMed ID: 28415636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
